Tanvex BioPharma, Inc. (TPE:6541)

Market Cap	13.85B +31.7%
Revenue (ttm)	224.83M +449.0%
Net Income	-1.36B
EPS	-6.18
Shares Out	264.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	828,406
Average Volume	847,381
Open	51.90
Previous Close	52.30
Day's Range	50.50 - 52.30
52-Week Range	48.10 - 82.00
Beta	0.02
RSI	46.60
Earnings Date	Mar 12, 2026

About Tanvex BioPharma

Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 200
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6541

Financial Performance

In 2024, Tanvex BioPharma's revenue was 34.68 million, a decrease of -43.53% compared to the previous year's 61.41 million. Losses were -1.38 billion, -35.35% less than in 2023.